Pancreatic Cancer Research

ResearcherUniversity of GroningenActive in the last 2 years

Vincent Erwin de Meijer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7900-5917; OpenAlex author ID A5046096257. Sources: OpenAlex.

Their work

Papers
58 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
122
Papers, trials and grants by year

2020: 3 papers · 2021: 7 papers · 2022: 7 papers · 2023: 7 papers · 2024: 12 papers · 2025: 10 papers · 2026: 12 papers

Papers 50 of 58

  1. Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial. Co-author DOI 10.1001/jamanetworkopen.2026.3861↗
  2. Transcriptome-Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant T… Co-author DOI 10.1002/ijc.70519↗
  3. The impact of age on quality of life, 90-day mortality, adjuvant chemotherapy, and survival after treatment for localized pancreatic cancer: A nationwide analy… Co-author DOI 10.1016/j.ejca.2026.116822↗
  4. Survival benefit of recurrence-focused treatment after surgery for pancreatic ductal adenocarcinoma: A propensity score matched analysis of patients from a Dut… Co-author DOI 10.1016/j.ejca.2026.117776↗
  5. Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. Co-author DOI 10.1016/j.ejso.2025.111165↗
  6. Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide population-based analysis. Co-author DOI 10.1016/j.hpb.2025.12.035↗
  7. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  8. Gastrointestinal symptoms and health-related quality of life before and after pancreatectomy for pancreatic cancer (GO-PANC): longitudinal nationwide study. Last author DOI 10.1093/bjs/znag122↗
  9. Continuity of care experienced by patients diagnosed with pancreatic cancer: nationwide multicentre study. Co-author DOI 10.1093/bjsopen/zrag033↗
  10. Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18639-1↗
  11. ASO Visual Abstract: Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18791-8↗
  12. The Value of Stereotactic Radiotherapy After FOLFIRINOX in Patients with Pancreatic Cancer with Vascular Contact-A Nationwide, Retrospective Cohort Study. Co-author DOI 10.3390/cancers18040700↗
  13. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  14. Survival scenarios of patients with localized and metastatic pancreatic adenocarcinoma: A population-based study. Co-author DOI 10.1002/ijc.35267↗
  15. Patterns of disease dissemination and survival in patients with synchronous and metachronous metastatic pancreatic adenocarcinoma: Nationwide population-based … Co-author DOI 10.1016/j.ejca.2025.115385↗
  16. 10-year survival after resection of pancreatic ductal adenocarcinoma with pathological re-examination of a nationwide cohort. Co-author DOI 10.1016/j.ejca.2025.116099↗
  17. Resectability stages of pancreatic cancer: nationwide reference. Co-author DOI 10.1093/bjs/znaf120↗
  18. Evaluation of Short and Long-term Outcomes After Resection in Patients With Locally Advanced Versus (Borderline) Resectable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006289↗
  19. Perineural Invasion is an Important Prognostic Factor in Patients With Radically Resected (R0) and Node-negative (pN0) Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006320↗
  20. Routine Imaging After Resection of Pancreatic Ductal Adenocarcinoma: Nationwide Utilization and Survival Analysis. Co-author DOI 10.1097/sla.0000000000006772↗
  21. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  22. Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study. Co-author DOI 10.6004/jnccn.2024.7091↗
  23. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.7872↗
  24. Preoperative chemoradiotherapy but not chemotherapy is associated with reduced risk of postoperative pancreatic fistula after pancreatoduodenectomy for pancrea… Co-author DOI 10.1016/j.surg.2024.01.029↗
  25. Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study. Co-author DOI 10.1093/jnci/djae070↗
  26. Predicting Long-term Disease-free Survival After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Cohort Study. Co-author DOI 10.1097/sla.0000000000006004↗
  27. Minimum and Optimal CA19-9 Response After Two Months Induction Chemotherapy in Patients With Locally Advanced Pancreatic Cancer: A Nationwide Multicenter Study. Co-author DOI 10.1097/sla.0000000000006021↗
  28. Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an i… Co-author DOI 10.1186/s13063-024-08223-5↗
  29. Correction: Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): prot… Co-author DOI 10.1186/s13063-024-08295-3↗
  30. Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy. Co-author DOI 10.1245/s10434-023-14650-6↗
  31. ASO Author Reflections: Nationwide Experience on Locally Advanced Pancreatic Cancer Surgery After Induction Chemotherapy in the Netherlands: A Stepping Stone f… Co-author DOI 10.1245/s10434-023-14704-9↗
  32. The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection: A Nationwide Analysis. Co-author DOI 10.1245/s10434-024-15070-w↗
  33. Prediction of Isolated Local Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Study. Co-author DOI 10.1245/s10434-024-15664-4↗
  34. The Difficulty of Detecting Occult Metastases in Patients with Potentially Resectable Pancreatic Cancer: Development and External Validation of a Preoperative … Co-author DOI 10.3390/jcm13061679↗
  35. The yield of staging laparoscopy for resectable and borderline resectable pancreatic cancer in the PREOPANC randomized controlled trial. Co-author DOI 10.1016/j.ejso.2022.12.011↗
  36. Population-based impact of COVID-19 on incidence, treatment, and survival of patients with pancreatic cancer. Co-author DOI 10.1016/j.hpb.2023.04.017↗
  37. Practice variation in venous resection during pancreatoduodenectomy for pancreatic cancer: A nationwide cohort study. Co-author DOI 10.1016/j.surg.2023.06.012↗
  38. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderl… Co-author DOI 10.1093/bjs/znad210↗
  39. Impact of complications after resection of pancreatic cancer on disease recurrence and survival, and mediation effect of adjuvant chemotherapy: nationwide, obs… Co-author DOI 10.1093/bjsopen/zrac174↗
  40. Outcome of Pancreatic Surgery During the First 6 Years of a Mandatory Audit Within the Dutch Pancreatic Cancer Group. Co-author DOI 10.1097/sla.0000000000005628↗
  41. Intraoperative Molecular Fluorescence Imaging of Pancreatic Cancer by Targeting Vascular Endothelial Growth Factor: A Multicenter Feasibility Dose-Escalation S… Co-author DOI 10.2967/jnumed.121.263773↗
  42. Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33916↗
  43. Preoperative predictors for early and very early disease recurrence in patients undergoing resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2021.09.004↗
  44. Age and prognosis in patients with pancreatic cancer: a population-based study. Co-author DOI 10.1080/0284186x.2021.2016949↗
  45. Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands: A Nationwide Analysis. Co-author DOI 10.1097/sla.0000000000004093↗
  46. Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11664-4↗
  47. Short- and Long-Term Outcomes of Pancreatic Cancer Resection in Elderly Patients: A Nationwide Analysis. Co-author DOI 10.1245/s10434-022-11831-7↗
  48. Correction to: Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic C… Co-author DOI 10.1245/s10434-022-12182-z↗
  49. Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of t… Co-author DOI 10.1002/jso.26567↗
  50. Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort. Co-author DOI 10.1016/j.ejso.2020.11.137↗

Closest collaborators

The 25 strongest of 122 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 48 shared papers, 2020–2026 · strength 7.29
  2. Ignace H. J. T. de Hingh · 43 shared papers, 2020–2026 · strength 6.37
  3. Martijn W.J. Stommel · 39 shared papers, 2020–2026 · strength 5.93
  4. Hjalmar C. van Santvoort · 40 shared papers, 2020–2026 · strength 5.89
  5. Izaak Quintus Molenaar · 39 shared papers, 2020–2026 · strength 5.62
  6. Bas Groot Koerkamp · 34 shared papers, 2020–2026 · strength 4.98
  7. Bert A. Bonsing · 30 shared papers, 2020–2026 · strength 4.52
  8. Lois A. Daamen · 27 shared papers, 2021–2026 · strength 4.20
  9. Sebastiaan Festen · 28 shared papers, 2021–2026 · strength 3.97
  10. Johanna W. Wilmink · 24 shared papers, 2020–2026 · strength 3.79
  11. Judith de Vos‐Geelen · 22 shared papers, 2020–2026 · strength 3.42
  12. Martijn Intven · 19 shared papers, 2021–2026 · strength 2.92
  13. Casper H.J. van Eijck · 18 shared papers, 2020–2026 · strength 2.67
  14. Geert Kazemier M · 18 shared papers, 2020–2026 · strength 2.61
  15. Hanneke W.M. van Laarhoven · 14 shared papers, 2020–2026 · strength 2.43
  16. Robert C. Verdonk · 15 shared papers, 2022–2026 · strength 2.36
  17. Vincent B. Nieuwenhuijs · 16 shared papers, 2020–2026 · strength 2.15
  18. Gijs A. Patijn · 15 shared papers, 2021–2026 · strength 2.01
  19. Marjolein Y.V. Homs · 11 shared papers, 2020–2026 · strength 2.00
  20. Lydia G. van der Geest · 11 shared papers, 2020–2026 · strength 1.97
  21. Iris W.J.M. van Goor · 12 shared papers, 2021–2026 · strength 1.95
  22. Vincent P. Groot · 12 shared papers, 2022–2026 · strength 1.85
  23. Thijs J. Schouten · 12 shared papers, 2021–2026 · strength 1.79
  24. Gert J. Meijer · 9 shared papers, 2022–2026 · strength 1.49
  25. Paul C. M. Andel · 8 shared papers, 2024–2026 · strength 1.43

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.